U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C4H9NO2S
Molecular Weight 135.185
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HOMOCYSTEINE

SMILES

N[C@@H](CCS)C(O)=O

InChI

InChIKey=FFFHZYDWPBMWHY-VKHMYHEASA-N
InChI=1S/C4H9NO2S/c5-3(1-2-8)4(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m0/s1

HIDE SMILES / InChI

Molecular Formula C4H9NO2S
Molecular Weight 135.185
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Homocysteine, an amino acid synthesized intracellularly by removal of the N-methyl group from the essential amino acid methionine. High plasma level of homocysteine is called hyperhomocysteinemia is a clinical biomarker for increased risk of cardiovascular disease, thromboembolic diseases, and myocardial infarction. It was shown, that hyperhomocysteinemia could be an independent risk factor for dementia and Alzheimer's disease. The falling of homocysteine concentrations in response to increasing B-group-vitamin status, have the hope that mental decline, or Alzheimer's disease, could be prevented by dietary modification or food fortification. Besides, homocysteine can behave as an anti-oxidant agent by increasing the antioxidant capacity of the tumor and endothelial cells.

Approval Year

PubMed

PubMed

TitleDatePubMed
Mutations in the regulatory domain of cystathionine beta synthase can functionally suppress patient-derived mutations in cis.
2001-03-15
Plasma folate, vitamin B(12), and homocyst(e)ine concentrations in preeclamptic and normotensive Peruvian women.
2001-03-01
Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition.
2001-03-01
Interaction of estrogen replacement therapy with the thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic vascular disease: a cross-sectional study of 275 hyperlipidemic women.
2001-03
Crystallization and preliminary X-ray crystallographic studies of recombinant human betaine-homocysteine S-methyltransferase.
2001-03
Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey.
2001-03
The effects of oral methionine and homocysteine on endothelial function.
2001-03
Evidence against oxidative stress as mechanism of endothelial dysfunction in methionine loading model.
2001-03
Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production.
2001-03
Hyperhomocysteinemia is associated with venous thrombosis in patients with short bowel syndrome.
2001-02-24
Genetic determinants of homocysteine thiolactonase activity in humans: implications for atherosclerosis.
2001-02-23
Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys.
2001-02-20
Differences between cysteine and homocysteine in the induction of deoxyribose degradation and DNA damage.
2001-02-15
Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease?
2001-02-15
[Folates, vitamin B12, homocysteine and neural tube defects].
2001-02-15
[Plasma homocysteine measurement: a study of pre-analytical variation factors for conditions for total plasma homocysteine concentration].
2001-02-15
Serum homocysteine and stroke in atrial fibrillation.
2001-02-06
Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin.
2001-02
Mutations in the gene for methylenetetrahydrofolate reductase, homocysteine levels, and vitamin status in women with a history of preeclampsia.
2001-02
Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.
2001-02
Hypercoagulable thrombophilic defects and hyperhomocysteinemia in patients with recurrent pregnancy loss.
2001-02
Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects.
2001-02
Determinants of changes in plasma homocysteine in hyperthyroidism and hypothyroidism.
2001-02
Homocysteine and stroke.
2001-02
Established and emerging cardiovascular risk factors.
2001-02
C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis.
2001-02
Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design.
2001-02
Crystallization and preliminary X-ray diffraction analysis of the active core of human recombinant cystathionine beta-synthase: an enzyme involved in vascular disease.
2001-02
Low seminal plasma folate concentrations are associated with low sperm density and count in male smokers and nonsmokers.
2001-02
Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans.
2001-02
Protein-bound uremic solutes: the forgotten toxins.
2001-02
Homocysteine, its metabolites, and B-group vitamins in renal transplant patients.
2001-02
Is there a role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells?
2001-02
Characterization of the zinc sites in cobalamin-independent and cobalamin-dependent methionine synthase using zinc and selenium X-ray absorption spectroscopy.
2001-01-30
[Homocysteine--CRP--lipoprotein (a). When do you evaluate the "new" risk factors].
2001-01-25
Unsuspected hyperhomocysteinemia in chronically anticoagulated patients.
2001-01
Longitudinal vitamin and homocysteine levels in normal pregnancy.
2001-01
[Homocysteine, endothelial dysfunction and cardiovascular risk: pathomechanisms and therapeutic options].
2001-01
Homocysteine stimulates the expression of monocyte chemoattractant protein-1 in endothelial cells leading to enhanced monocyte chemotaxis.
2001-01
[Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease].
2001-01
Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulph-hydryls before and after co-factor supplementation in haemodialysis patients.
2001-01
Plasma total homocysteine concentration in nephrotic patients with idiopathic membranous nephropathy.
2001-01
The direct electrochemistry of myoglobin at a DL-homocysteine self-assembled gold electrode.
2001-01
Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men.
2001-01
Relationships between homocysteine, folate and vitamin B12 levels with the methylenetetrahydrofolate reductase polymorphism, in Indians from Western Venezuela.
2001-01
Homocysteine: a new cardiac risk factor?
2001-01
Cause and management of heart failure in patients with chronic renal disease.
2001-01
Risk factors for atherosclerosis in survivors of myocardial infarction and their spouses: comparison to controls without personal and family history of atherosclerosis.
2001-01
Activation of the ventrolateral periaqueductal gray reduces locomotion but not mean arterial pressure in awake, freely moving rats.
2001
Homocysteine and human reproduction.
2000
Patents
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:20:34 GMT 2025
Edited
by admin
on Mon Mar 31 18:20:34 GMT 2025
Record UNII
0LVT1QZ0BA
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HOMOCYSTEINE
MI  
Systematic Name English
NSC-43117
Preferred Name English
HOMOCYSTEINE, L-
Systematic Name English
L-HOMOCYSTEINE
Systematic Name English
(S)-2-AMINO-4-MERCAPTOBUTANOIC ACID
Systematic Name English
HOMOCYSTEINE [MI]
Common Name English
(S)-HOMOCYSTEINE
Systematic Name English
NSC-118376
Code English
Classification Tree Code System Code
LOINC 54301-7
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 44373-9
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 13758-8
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 2428-1
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 44375-4
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 49727-1
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 55878-3
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 44374-7
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
NCI_THESAURUS C73539
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 32690-0
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 26582-7
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 10969-4
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 21056-7
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 44377-0
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 12470-1
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 44376-2
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 54300-9
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 44719-3
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 55877-5
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 13965-9
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
LOINC 32020-0
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
Code System Code Type Description
CHEBI
17588
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
CAS
6027-13-0
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
CHEBI
58199
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
WIKIPEDIA
HOMOCYSTEINE
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
DRUG BANK
DB04422
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
FDA UNII
0LVT1QZ0BA
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
CHEBI
17230
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
NCI_THESAURUS
C105949
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
NSC
43117
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
MERCK INDEX
m6042
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY Merck Index
MESH
D006710
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
EPA CompTox
DTXSID3041039
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
ECHA (EC/EINECS)
227-891-0
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
PUBCHEM
91552
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
NSC
118376
Created by admin on Mon Mar 31 18:20:34 GMT 2025 , Edited by admin on Mon Mar 31 18:20:34 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> SUBSTRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY